211 related articles for article (PubMed ID: 20693416)
1. Effect of hepatitis C virus infection on the mRNA expression of drug transporters and cytochrome p450 enzymes in chimeric mice with humanized liver.
Kikuchi R; McCown M; Olson P; Tateno C; Morikawa Y; Katoh Y; Bourdet DL; Monshouwer M; Fretland AJ
Drug Metab Dispos; 2010 Nov; 38(11):1954-61. PubMed ID: 20693416
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients.
Nakai K; Tanaka H; Hanada K; Ogata H; Suzuki F; Kumada H; Miyajima A; Ishida S; Sunouchi M; Habano W; Kamikawa Y; Kubota K; Kita J; Ozawa S; Ohno Y
Drug Metab Dispos; 2008 Sep; 36(9):1786-93. PubMed ID: 18515332
[TBL] [Abstract][Full Text] [Related]
3. Expression of human cytochromes P450 in chimeric mice with humanized liver.
Katoh M; Matsui T; Nakajima M; Tateno C; Kataoka M; Soeno Y; Horie T; Iwasaki K; Yoshizato K; Yokoi T
Drug Metab Dispos; 2004 Dec; 32(12):1402-10. PubMed ID: 15383493
[TBL] [Abstract][Full Text] [Related]
4. Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
Sanoh S; Horiguchi A; Sugihara K; Kotake Y; Tayama Y; Ohshita H; Tateno C; Horie T; Kitamura S; Ohta S
Drug Metab Dispos; 2012 Feb; 40(2):322-8. PubMed ID: 22048522
[TBL] [Abstract][Full Text] [Related]
5. Validation of uPA/SCID mouse with humanized liver as a human liver model: protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases by LC-MS/MS.
Ohtsuki S; Kawakami H; Inoue T; Nakamura K; Tateno C; Katsukura Y; Obuchi W; Uchida Y; Kamiie J; Horie T; Terasaki T
Drug Metab Dispos; 2014 Jun; 42(6):1039-43. PubMed ID: 24711249
[TBL] [Abstract][Full Text] [Related]
6. Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver.
Hasegawa M; Tahara H; Inoue R; Kakuni M; Tateno C; Ushiki J
Drug Metab Dispos; 2012 Mar; 40(3):474-80. PubMed ID: 22126990
[TBL] [Abstract][Full Text] [Related]
7. Development of Murine Cyp3a Knockout Chimeric Mice with Humanized Liver.
Kato K; Ohbuchi M; Hamamura S; Ohshita H; Kazuki Y; Oshimura M; Sato K; Nakada N; Kawamura A; Usui T; Kamimura H; Tateno C
Drug Metab Dispos; 2015 Aug; 43(8):1208-17. PubMed ID: 25979261
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities.
Ohtsuki S; Schaefer O; Kawakami H; Inoue T; Liehner S; Saito A; Ishiguro N; Kishimoto W; Ludwig-Schwellinger E; Ebner T; Terasaki T
Drug Metab Dispos; 2012 Jan; 40(1):83-92. PubMed ID: 21994437
[TBL] [Abstract][Full Text] [Related]
9. In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver.
Katoh M; Matsui T; Nakajima M; Tateno C; Soeno Y; Horie T; Iwasaki K; Yoshizato K; Yokoi T
Drug Metab Dispos; 2005 Jun; 33(6):754-63. PubMed ID: 15769886
[TBL] [Abstract][Full Text] [Related]
10. Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor.
Kamiya N; Iwao E; Hiraga N; Tsuge M; Imamura M; Takahashi S; Miyoshi S; Tateno C; Yoshizato K; Chayama K
J Gen Virol; 2010 Jul; 91(Pt 7):1668-77. PubMed ID: 20164258
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiles of drug-metabolizing enzymes and transporters with an overexpression of hepatocyte growth factor.
Kakizaki S; Yamazaki Y; Kosone T; Horiguchi N; Sohara N; Sato K; Takagi H; Yoshinari K; Mori M
Liver Int; 2007 Feb; 27(1):109-19. PubMed ID: 17241389
[TBL] [Abstract][Full Text] [Related]
12. The effect of Nrf2 knockout on the constitutive expression of drug metabolizing enzymes and transporters in C57Bl/6 mice livers.
Anwar-Mohamed A; Degenhardt OS; El Gendy MA; Seubert JM; Kleeberger SR; El-Kadi AO
Toxicol In Vitro; 2011 Jun; 25(4):785-95. PubMed ID: 21281708
[TBL] [Abstract][Full Text] [Related]
13. Expression of human phase II enzymes in chimeric mice with humanized liver.
Katoh M; Matsui T; Okumura H; Nakajima M; Nishimura M; Naito S; Tateno C; Yoshizato K; Yokoi T
Drug Metab Dispos; 2005 Sep; 33(9):1333-40. PubMed ID: 15932951
[TBL] [Abstract][Full Text] [Related]
14. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
Vanwolleghem T; Meuleman P; Libbrecht L; Roskams T; De Vos R; Leroux-Roels G
Gastroenterology; 2007 Oct; 133(4):1144-55. PubMed ID: 17919490
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus infection in mouse hepatoma cells co-expressing human CD81 and Sip-L.
Yeh CT; Lai HY; Yeh YJ; Cheng JC
Biochem Biophys Res Commun; 2008 Jul; 372(1):157-61. PubMed ID: 18474223
[TBL] [Abstract][Full Text] [Related]
16. Chimeric mice with humanized liver.
Katoh M; Tateno C; Yoshizato K; Yokoi T
Toxicology; 2008 Apr; 246(1):9-17. PubMed ID: 18248870
[TBL] [Abstract][Full Text] [Related]
17. Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds.
Chen C; Stock JL; Liu X; Shi J; Van Deusen JW; DiMattia DA; Dullea RG; de Morais SM
Drug Metab Dispos; 2008 Sep; 36(9):1840-5. PubMed ID: 18556442
[TBL] [Abstract][Full Text] [Related]
18. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis.
Mirandola S; Realdon S; Iqbal J; Gerotto M; Dal Pero F; Bortoletto G; Marcolongo M; Vario A; Datz C; Hussain MM; Alberti A
Gastroenterology; 2006 May; 130(6):1661-9. PubMed ID: 16697730
[TBL] [Abstract][Full Text] [Related]
19. Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma.
Tsunedomi R; Iizuka N; Hamamoto Y; Uchimura S; Miyamoto T; Tamesa T; Okada T; Takemoto N; Takashima M; Sakamoto K; Hamada K; Yamada-Okabe H; Oka M
Int J Oncol; 2005 Sep; 27(3):661-7. PubMed ID: 16077914
[TBL] [Abstract][Full Text] [Related]
20. Drug transporter and cytochrome P450 mRNA expression in human ocular barriers: implications for ocular drug disposition.
Zhang T; Xiang CD; Gale D; Carreiro S; Wu EY; Zhang EY
Drug Metab Dispos; 2008 Jul; 36(7):1300-7. PubMed ID: 18411399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
